Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.00

€1.00

2.780%
0.0272
2.780%
€1.79
 
16:14 / Tradegate WKN: A1W50M / Symbol: FATE / Name: Fate / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Fate Therapeutics Inc. Stock

There is an upward development for Fate Therapeutics Inc. compared to yesterday, with an increase of €0.027 (2.780%).
With 1 Sell predictions and 1 Buy predictions the community sentiment towards the Fate Therapeutics Inc. stock is not clear.
At the moment Fate Therapeutics Inc. has reached the predicted target price of 1 €, with a current price of 1.0 €.
For the coming years our community has positive and negative things to say abot the Fate Therapeutics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Balance Sheet Risk" there were negative voices in the community.

Pros and Cons of Fate Therapeutics Inc. in the next few years

Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
B****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Fate Therapeutics Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Fate Therapeutics Inc. 2.780% 3.409% -25.860% -66.410% -35.969% -96.687% -96.966%
Krystal Biotech 1.730% 6.049% 5.696% -28.994% -16.491% 77.762% -
Ardelyx Inc. -0.790% 10.295% 21.544% -23.805% -21.027% 468.673% -37.264%
Evolus Inc -3.640% 0.662% -7.317% -26.923% -27.619% -41.085% 162.069%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

The financials of Fate Therapeutics, Inc. (US symbol FATE) paint a rather challenging picture amid the Biotechnology & Medical Research industry landscape. An examination of the company's recent performance reveals a combination of substantial operational struggles and notable potential for growth, accompanied by a significant cash burn. While their commitment to innovative research is commendable, the persistent negative net income and high expenditures raise concerns about their short-term viability.

Delving into the specifics, several pros and cons delineate the financial status of Fate Therapeutics.

Market Capitalization: Sitting at approximately $540.5 million, the company's market valuation isn’t inconsequential. Despite the struggles, a solid market cap can serve as a buffer for future fundraising or acquisition opportunities.

Comments

Fate Therapeutics, Inc. (NASDAQ: FATE) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Ratings data for FATE provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 16.42%
Target price 1.787
Change
Ends at 14.05.26

Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target lowered by analysts at Barclays PLC from $10.00 to $2.00. They now have an "overweight" rating on the stock.
Ratings data for FATE provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -71.37%
Target price 5.599
Change
Ends at 17.06.25

Fate Therapeutics, Inc. (NASDAQ: FATE) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $6.00 price target on the stock, up previously from $4.00.
Ratings data for FATE provided by MarketBeat
Show more